The Biotechnology Innovation Organization has joined a legal challenge aimed at the US Centers for Medicare & Medicaid Services’ proposed Global Benchmark for Efficient Drug Pricing model, known as GLOBE. BIO, along with two California-based biotech trade groups, filed a complaint seeking to halt the demonstration. The groups argue the program exceeds Medicare’s statutory authority. A CMS response was not immediately provided. For biotech stakeholders, the case directly targets a mechanism that could reshape pricing expectations across indications and influence contracting strategies for specialty therapies.